Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Neuroendocrine 1 Advanced Head and Neck Carcinoma 1

Interventions

Everolimus 9 Cisplatin 8 Temozolomide 6 Nivolumab 5 Etoposide 5 Carboplatin 5 Bevacizumab 5 lutetium Lu 177 dotatate 4 Capecitabine 4 pembrolizumab 3 Irinotecan 3 sintilimab 2 dostarlimab 2 cabozantinib 2 azaspirane 2 avelumab 2 atezolizumab 2 Paclitaxel 2 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2 Ipilimumab 2 Immunoglobulin G 2 IFL protocol 2 Fluorouracil 2 Fluorodeoxyglucose F18 2 Disulfides 2 zimberelimab 1 surufatinib 1 selinexor 1 pertuzumab 1 pasireotide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Neuroendocrine × Radiopharmaceuticals × Clear all

NCT02236910 2024-10-15

Lu-DOTA-TATE

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 2 Unknown

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡